Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 16, 2024 08:03 ET | Source: Asklepios BioPharmaceutical, Inc. (AskBio)

AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease

Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...
April 09, 2024 08:00 ET | Source: Asklepios BioPharmaceutical, Inc. (AskBio)

AskBio Names Mansuo Shannon Chief Scientific Officer

Research Triangle Park, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyCo-Founder and former Chief...
February 13, 2024 08:10 ET | Source: Asklepios BioPharmaceutical, Inc. (AskBio)

First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure

Berlin, Germany and Research Triangle Park, NC, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1002 is an investigational gene therapy for the treatment of adults with...
January 05, 2024 08:11 ET | Source: Asklepios BioPharmaceutical, Inc. (AskBio)

AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)

Research Triangle Park, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer...
January 04, 2024 02:30 ET | Source: Asklepios BioPharmaceutical, Inc. (AskBio)

AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint

Berlin, Germany/Research Triangle Park, North Carolina, USA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (AAV2-GDNF), an investigational gene therapy for the...